Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
Authors:
- Shuzo SatoSSShuzo Sato
- Haruki MatsumotoHMHaruki Matsumoto
- Jumpei TemmokuJTJumpei Temmoku
- Yuya FujitaYFYuya Fujita
- Naoki MatsuokaNMNaoki Matsuoka
- Makiko Yashiro-FuruyaMYMakiko Yashiro-Furuya
- Tomoyuki AsanoTATomoyuki Asano
- Eiji SuzukiESEiji Suzuki
- Hiroshi WatanabeHWHiroshi Watanabe
- Takashi KannoTKTakashi Kanno
- Kiyoshi MigitaKMKiyoshi Migita
Open Access
Abstract
Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (p < 0.01), and elderly patients significantly received tacrolimus (TAC) (p < 0.01) or salazosulfapyridine (SASP; p = 0.01) than younger patients. The overall retention and infection-free survival rates were similar between the two groups. Conclusion: Elderly RA patients showed sustained retention rates compared to younger RA patients. TAC and SASP can help to maintain sustained retention rates in elderly RA patients.Keywords
This publication has 32 references indexed in Scilit:
- Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registryRheumatology, 2016
- Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritisModern Rheumatology, 2016
- Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of TacrolimusDrugs in R&D, 2015
- Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC RegistryModern Rheumatology, 2015
- Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritisBMJ Open, 2014
- Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trialsScandinavian Journal of Rheumatology, 2010
- Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patientsRheumatology, 2005
- Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: Effect of FK506, an inhibitor of T cell activationInflammation Research, 2004
- FK506 potently inhibits T cell activation induced TNF‐α and IL‐1β production in vitro by human peripheral blood mononuclear cellsBritish Journal of Pharmacology, 2000
- Human aging and diseaseJournal of Chronic Diseases, 1963